Wall Street Zen Upgrades Stryker (NYSE:SYK) to Buy

Stryker (NYSE:SYK) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Sunday.

SYK has been the subject of a number of other reports. Rothschild Redb upgraded Stryker to a “hold” rating in a research report on Thursday, September 18th. BTIG Research reaffirmed a “buy” rating and issued a $410.00 price target on shares of Stryker in a research note on Friday, November 14th. Redburn Partners set a $420.00 price objective on shares of Stryker in a research report on Thursday, September 18th. Truist Financial decreased their target price on shares of Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a report on Thursday, December 18th. Finally, Rothschild & Co Redburn started coverage on shares of Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target for the company. Thirteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $431.84.

Stryker Stock Performance

Shares of NYSE SYK opened at $356.50 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. The stock’s fifty day moving average price is $365.09 and its two-hundred day moving average price is $377.26. Stryker has a one year low of $329.16 and a one year high of $406.19. The firm has a market cap of $136.33 billion, a price-to-earnings ratio of 46.85, a P/E/G ratio of 2.51 and a beta of 0.89.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The company had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter last year, the firm earned $2.87 earnings per share. The company’s revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, equities analysts forecast that Stryker will post 13.47 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Preston Wendell Wells sold 165 shares of the business’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the sale, the chief financial officer owned 6,694 shares in the company, valued at $2,449,200.72. The trade was a 2.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the transaction, the director owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 522,118 shares of company stock valued at $185,381,932. 5.20% of the stock is currently owned by insiders.

Institutional Trading of Stryker

Institutional investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC raised its stake in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in Stryker by 79.2% in the first quarter. T. Rowe Price Investment Management Inc. now owns 3,532 shares of the medical technology company’s stock worth $1,315,000 after purchasing an additional 1,561 shares in the last quarter. Compound Planning Inc. lifted its stake in Stryker by 14.5% in the first quarter. Compound Planning Inc. now owns 2,878 shares of the medical technology company’s stock valued at $1,071,000 after buying an additional 365 shares during the period. AlphaQuest LLC boosted its holdings in shares of Stryker by 21,855.6% during the 1st quarter. AlphaQuest LLC now owns 1,976 shares of the medical technology company’s stock worth $736,000 after buying an additional 1,967 shares in the last quarter. Finally, Sax Wealth Advisors LLC acquired a new stake in shares of Stryker during the 1st quarter worth approximately $229,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.